EP0089854A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Vaccine against DNA viruses
Assignee: University of Birmingham
•
Filing: 1983-03-23
•
Granted: —
•
Expires: 2003-03-23
Abstract
Abstract A vaccine against a DNA virus, for example, Herpes simplex virus, is prepared by incubating a cell sample which has been infected with the virus releasing the nuclei in the infected cell material from the cytoplasmic fraction of that material, chemically fixing the polypeptide chain in the cytoplasmic fraction, and forming a precipitate which includes the virus antigens in the cytoplasmic fraction, the precipitate providing the active constituent of the vaccine. A characteristic strain of the virus is preferred, and transfers its characteristics to the vaccine so that vaccinated subjects may subsequently be distinguished from infected subjects.
Inventors
- 👤 Gorden Robert Bruce Skinner
- 👤 Alexander Buchan
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-03 07:26
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/12; C; C12; C12N; C12N15/00; A61K39/245; A61K2039/51; A61K2039/525; A61K2039/5252; A61K2039/555; A61K2039/55505; C12N2710/00; C12N2710/00011; C12N2710/16011; C12N2710/16611; C12N2710/16634
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
67 words
A method of preparing a vaccine against a DNA virus includes the steps of incubating a cell sample which has been infected with the viurus, and forming a precipitate which includes the virus antigens in the infected cell sample, the precipitate providing the active constituent of the vaccine, characterised in that before forming said precipitate the polypeptide chains in said cytoplasmic fractions are fixed by chemical reaction.
Claim 2
Independent Claim
67 words
A method of preparing a vaccine against a DNA virus includes the steps of incubating a cell sample which has been infected with the viurus, and forming a precipitate which includes the virus antigens in the infected cell sample, the precipitate providing the active constituent of the vaccine, characterised in that before forming said precipitate the polypeptide chains in said cytoplasmic fractions are fixed by chemical reaction.
Claim 3
Dependent Claim
35 words
A method as claimed in claim 1 which includes the step of releasing the nuclei of the infected cell material from the cytoplasmic fraction of that material, said precipitate being formed from said cytoplasmic fraction.
Claim 4
Dependent Claim
26 words
A method as claimed in claim 2 in which fixing of the polypeptide chains is effected by addition of formaldehyde or glutaraldehyde to said cytoplasmic fraction.
Claim 5
Dependent Claim
23 words
A method as claimed in claim 2 which includes the steps of separating and discarding the released nuclei, and retaining the cytoplasmic fraction.
Claim 6
Dependent Claim
36 words
A method as claimed in claim 2 in which said precipitate is formed by steps which include reacting said cytoplasmic fraction with antibodies to the proteins of said virus, and separating the antigen/antibody precipitate so formed.
Claim 7
Independent Claim
43 words
A method as claimed in claim .2 in which said precipitate is formed by steps which include reacting said cytoplasmic fraction with antibodies to the proteins in said cell sample, separating and discarding the antigen/antibody precipitate so formed, and precipitating the remaining proteins.
Claim 8
Dependent Claim
33 words
A method as claimed in claim 2, which includes the steps of cultivating said cells in a serum, and subsequently subjecting the cultivated cells to serum deprivation prior to infection with said virus.
Claim 9
Dependent Claim
39 words
A method as claimed in claim 7 in which said precipitate is formed by steps which include the addition to said cytoplasmic fraction of an organic solvent which reacts with water in preference to the proteins in said sample.
Claim 10
Dependent Claim
23 words
A method as claimed in claim 8 in which said organic solvent is selected from the group which includes acetone, ethanol and methanol.
Claim 11
Dependent Claim
24 words
A method as claimed in claim 8 or claim 9 in which 'the temperature of said solvent is between 0°C and - 300 C.
Claim 12
Independent Claim
23 words
A method as claimed in any one of claims 5, 6 or 7 which includes the addition of said precipitate to aluminium hydroxide.
Claim 13
Dependent Claim
23 words
A method as claimed in claim 7, in which said precipitate is formed by the addition of aluminium hydroxide to said cytoplasmic fraction.
Claim 14
Dependent Claim
16 words
A vaccine against DNA virus, when prepared by a method as claimed in any preceding claim.
Claim 15
Dependent Claim
24 words
A vaccine against Herpes simplex virus, characterized by the presence of proteins of the molecular weights substantially as indicated in Figures 1 and 2.
Claim 16
Dependent Claim
24 words
A vaccine against Herpes simplex virus, characterized by the presence of proteins of the molecular weights substantially as indicated in Figures 1 and 2.
Claim 17
Dependent Claim
20 words
A vaccine against Herpes simplex virus, characterized by the absence of proteins from serum used in preparation of the vaccine.
Claim 18
Dependent Claim
20 words
A vaccine against Herpes simplex virus, characterized by the absence of proteins from serum used in preparation of the vaccine.
Claim 19
Dependent Claim
21 words
A vaccine as claimed in claim 15, characterized by the absence of proteins from cells used in preparation of the vaccine.
Claim 20
Independent Claim
25 words
A method of protecting a subject against Herpes simplex virus, comprising administration of a vaccine as claimed in any of claims 13, 14 or 15.
Claim 21
Dependent Claim
24 words
A herpes simplex type 1 virus characterised by the presence of proteins of the undecular weights substantially as indicated in Figures 1 and 2.
Claim 22
Dependent Claim
24 words
A herpes simplex type 1 virus characterised by the presence of proteins of the undecular weights substantially as indicated in Figures 1 and 2.
Claim 23
Dependent Claim
20 words
A vaccine for use against Herpes simplex type 2, said vaccine being derived from a Herpes simplex type 1 virus.
Claim 24
Dependent Claim
20 words
A vaccine for use against Herpes simplex type 2, said vaccine being derived from a Herpes simplex type 1 virus.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.